Short Interest in InterCure Ltd. (NASDAQ:INCR) Increases By 312.7%

Posted by John Perry on May 15th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totaling 31,467 shares, a growth of 312.7% from the April 15th total of 7,624 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 68,401 shares, the short-interest ratio is currently 0.5 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of InterCure in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, InterCure has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on InterCure

InterCure Stock Performance

InterCure stock remained flat at $0.82 during mid-day trading on Friday. The company had a trading volume of 5,240 shares, compared to its average volume of 47,494. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $1.01. The firm has a market cap of $44.84 million, a PE ratio of 27.33 and a beta of 1.24. InterCure has a fifty-two week low of $0.68 and a fifty-two week high of $1.77. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.48 and a quick ratio of 0.97.

InterCure (NASDAQ:INCR – Get Free Report) last posted its quarterly earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $23.15 million during the quarter.

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.